XOMA Royalty Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

XOMA hat ein Gesamteigenkapital von $82.3M und eine Gesamtverschuldung von $120.7M, was einen Verschuldungsgrad von 146.6% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $219.4M bzw. $137.1M.

Wichtige Informationen

146.6%

Verhältnis von Schulden zu Eigenkapital

US$120.67m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$136.64m
Eigenkapital	US$82.34m
Gesamtverbindlichkeiten	US$137.08m
Gesamtvermögen	US$219.42m

Jüngste Berichte zur Finanzlage

Recent updates

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

Jun 29

Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?

Apr 03

Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?

Sep 01

Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

Aug 11

XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M

Aug 04

Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

May 08

Xoma Gets The Spotlight

Sep 02

Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

Aug 20

We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

May 13

Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

May 11

XOMA EPS misses by $0.55, misses on revenue

May 06

XOMA gets milestone payment from Janssen Biotech

May 03

XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality

Mar 17

Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be

Mar 16

Is XOMA Corporation (NASDAQ:XOMA) Popular Amongst Institutions?

Mar 09

Did You Miss XOMA's (NASDAQ:XOMA) Impressive 140% Share Price Gain?

Feb 02

XOMA: A Royalty Aggregator To Watch

Jan 04

XOMA (NASDAQ:XOMA) Has Debt But No Earnings; Should You Worry?

Dec 29

XOMA prices $22M offering of series A cumulative perpetual preferred stock

Dec 11

Could The XOMA Corporation (NASDAQ:XOMA) Ownership Structure Tell Us Something Useful?

Dec 01

XOMA earns $2M milestone payment from Takeda

Nov 16

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: XOMADie kurzfristigen Aktiva des Unternehmens ($146.9M) übersteigen seine kurzfristigen Passiva ($15.5M).

Langfristige Verbindlichkeiten: XOMADie kurzfristigen Vermögenswerte des Unternehmens ($146.9M) übersteigen seine langfristigen Verbindlichkeiten ($121.5M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: XOMA über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: XOMADas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 94% auf 146.6% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: XOMA auf der Grundlage seines derzeitigen freien Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.

Vorhersage Cash Runway: XOMA über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt, wenn der freie Cashflow weiterhin mit historischen Raten von 9.8% pro Jahr wächst

XOMA Royalty Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?

Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

XOMA (NASDAQ:XOMA) Has Debt But No Earnings; Should You Worry?

Recent updates

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares

Consensus revenue estimates increase by 64%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Kinnate Biopharma Inc. (NasdaqGS:KNTE).

XOMA Corporation, Annual General Meeting, May 15, 2024

Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

XOMA Corporation (NasdaqGM:XOMA) announces an Equity Buyback for $50 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 58%

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.53 loss in 2Q 2022)

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 33%

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improved over the past week

XOMA Corporation Appoints Owen Hughes as Interim Chief Executive Officer

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Price target increased to US$62.50

Consensus revenue estimates fall by 65%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?

Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M

Investor sentiment deteriorated over the past week

CEO & Chairman of the Board exercised options and sold US$645k worth of stock

Investor sentiment improved over the past week

XOMA Corporation(NasdaqGM:XOMA) dropped from Russell 2000 Dynamic Index

Investor sentiment improved over the past week

Consensus revenue estimates fall by 14%

Consensus revenue estimates increase by 12%

Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$62.50

Now 24% undervalued

XOMA Corporation, Annual General Meeting, May 18, 2022

Investor sentiment improved over the past week

Now 20% undervalued

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.098 loss in 3Q 2020)

Investor sentiment improved over the past week

Price target increased to US$49.00

Price target decreased to US$46.00

Investor sentiment deteriorated over the past week

Xoma Gets The Spotlight

Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade

Investor sentiment deteriorated over the past week

Consensus revenue estimates fall to US$9.98m

Consensus EPS estimates increase to -US$0.83

Second quarter 2021 earnings released: US$0.31 loss per share (vs US$0.33 loss in 2Q 2020)

Price target increased to US$52.33

CEO & Director recently sold US$303k worth of stock

Investor sentiment improved over the past week

We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right

Consensus EPS estimates fall to -US$1.00

Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?

First quarter 2021 earnings released: US$0.70 loss per share (vs US$0.49 loss in 1Q 2020)

XOMA EPS misses by $0.55, misses on revenue

XOMA gets milestone payment from Janssen Biotech

Investor sentiment improved over the past week

Key Executive exercised options to buy US$212k worth of stock.

XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality

Consensus revenue estimates increase to US$17.1m

Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be

Full year 2020 earnings released: EPS US$0.82 (vs US$0.23 loss in FY 2019)